HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 285/4/E845    most recent 00130.2003v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Moore, M. C. Articles by Cherrington, A. D. Search for Related Content PubMed PubMed Citation Articles by Moore, M. C. Articles by Cherrington, A. D.

Chronic hepatic artery ligation does not prevent liver from differentiating portal vs. peripheral glucose delivery

Department of Molecular Physiology and Biophysics and Diabetes Research and Training Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0615

Submitted 25 March 2003 ; accepted in final form 23 May 2003

Infusion of glucose into the hepatic artery blocks the stimulatory effect of the "portal signal" on net hepatic glucose uptake (NHGU) during portal glucose delivery. We hypothesized that hepatic artery ligation (HAL) would result in enhanced NHGU during peripheral glucose infusion because the arterial glucose concentration would be perceived as lower than that in the portal vein. Fourteen dogs underwent HAL 16 days before study. Conscious 42-h-fasted dogs received somatostatin, intraportal insulin, and glucagon infusions at fourfold basal and at basal rates, respectively, and peripheral glucose infusion to create hyperglycemia. After 90 min (period 1), seven dogs (HAL_po) received intraportal glucose (3.8 mg · kg^–1 · min^–1) and seven (HAL_pe) continued to receive only peripheral glucose for 90 min (period 2). These two groups were compared with nine non-HAL control dogs (control) treated as were HAL_pe. During period 2, the arterial plasma insulin concentrations (24 ± 3, 20 ± 1, and 24 ± 2 µU/ml) and hepatic glucose loads (39.1 ± 2.5, 43.8 ± 2.9, and 37.7 ± 3.7 mg · kg^–1 · min^–1) were not different in HAL_pe, HAL_po, and control, respectively. HAL_po exhibited greater (P < 0.05) NHGU than HAL_pe and control (3.1 ± 0.3, 2.0 ± 0.4, and 2.0 ± 0.1 mg · kg^–1 · min^–1, respectively). Net hepatic carbon retention was approximately twofold greater (P < 0.05) in HAL_po than in HAL_pe and control. NHGU and net hepatic glycogen synthesis during peripheral glucose infusion were not enhanced by HAL. Even though there exists an intrahepatic arterial reference site for the portal vein glucose concentration, the failure of HAL to result in enhanced NHGU during peripheral glucose infusion suggests the existence of one or more comparison sites outside the liver.

liver glucose uptake; portal vein

This article has been cited by other articles:

				M. C. Moore, C. A. DiCostanzo, M. S. Smith, B. Farmer, T. D. Rodewald, D. W. Neal, P. E. Williams, and A. D. Cherrington Hepatic portal venous delivery of a nitric oxide synthase inhibitor enhances net hepatic glucose uptake Am J Physiol Endocrinol Metab, April 1, 2008; 294(4): E768 - E777. [Abstract] [Full Text] [PDF]

				M. Nishizawa, M. Shiota, M. C. Moore, S. M. Gustavson, D. W. Neal, and A. D. Cherrington Intraportal administration of neuropeptide Y and hepatic glucose metabolism Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1197 - R1204. [Abstract] [Full Text] [PDF]